Strategic partnerships Cyrus actively partners with leading biotech and pharma companies and research institutes to advance discovery to the clinic, presenting opportunities to pursue co-development, licensing, or joint programs with potential partners such as Selecta Biosciences, MIT/Broad Institute collaborations, and OpenFold.

Early-stage pipeline As a pre-clinical stage biotech with an early pipeline of innovative protein-based programs, there are opportunities to engage in collaborations for preclinical studies, technology licensing, or platform-enabled project launches to de-risk and accelerate partner programs.

Proven platform Cyrus builds on the Rosetta-based protein design platform and a track record of 90+ industry collaborations, suggesting sales angles around licensing access to its design software, bespoke protein engineering, and computational screening capabilities.

Financial readiness With notable Series B financing and strategic acquisitions (e.g., Orthogonal Biologics) and revenue in the low tens of millions, Cyrus is positioned to explore bigger collaborations, strategic investments, and milestone-driven deals that align with partner pipelines.

Market expansion signals Recent alliances spanning autoimmune and immune-related indications, autoimmune tolerogenic approaches, and safety-focused gene editing collaborations indicate growing demand for engineered therapeutics; this trend supports cross-domain outreach to pharmaceutical companies seeking next-generation biologics and safer protein therapeutics.